Trial reportBritish journal of cancer2007
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Trial report in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).Gastroenterology · 2021Pooled it
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.Biomedicines · 2024Review
- Therapeutic Value of Estrogen Receptor α in Hepatocellular Carcinoma Based on Molecular Mechanisms.Journal of clinical and translational hepatology · 2022Review
- Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2021Review
- Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.Journal of hepatocellular carcinoma · 2021Review
- Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.International journal of molecular sciences · 2019Review
- Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.BMC cancer · 2017Article
- Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Diseases (Basel, Switzerland) · 2015Review
- Quality of life and hepatocellular carcinoma.Journal of gastrointestinal oncology · 2014Review
- Systemic therapy of hepatocellular carcinoma: current status and future perspectives.World journal of gastroenterology · 2014Review
- Adjuvant tamoxifen influences the lipid profile in breast cancer patients.Breast care (Basel, Switzerland) · 2014Article
- [Diagnosis of and therapy for hepatocellular carcinoma].Zeitschrift fur Gastroenterologie · 2013Article
- Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.Asian journal of andrology · 2011Article
- Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.Journal of cancer research and clinical oncology · 2009Article
- Accomplishments in 2007 in the management of hepatobiliary cancers.Gastrointestinal cancer research : GCR · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC). A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment group) or TMX alone (n=53; control group). The clinical, biological and tumoural parameters were recorded every 3 months until death. Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes. Univariate and multivariate analyses were performed for assessment of specific prognostic factors. The median survival was 3 months (95% CI 1.4-4.6) for the experimental treatment group and 6 months (CI 95% 2-10) for the control group (P=0.609). There was no difference in terms of alpha-foetoprotein (alpha-FP) decrease, tumour regression, improvement of quality of life and prevention of variceal bleeding between the two groups. Variables associated with a better survival in the multivariate analysis were: presence of cirrhosis, alpha-FP level <400 ng ml(-1) and Okuda stage I. The combination of octreotide LAR and TMX does not influence survival, tumour progression or quality of life in patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.